A medication for treatment of hereditary angioedema in patients whose age is above is 18 years namely Firazyr (22150, icatibant solution) became a subject for voting in   FDA Pulmonary-Allergy Drugs Advisory Committee. The votes were 11 of 12 in favour of Firazyr. The committee’s recommendations are although void; however FDA favours Committee’s advice. But the Read more